Idebenone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Idebenone: From Mitochondrial Protection to Hepatic Porphyria
One-Sentence Summary
Idebenone is a synthetic coenzyme Q10 analogue best known for its mitochondrial electron-transport and antioxidant activity; no confirmed original approved indication is documented in this dataset, and the drug is not currently marketed in Finland. The TxGNN model predicts it may be effective for hepatic porphyria, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure graph-based inference with no direct experimental backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in current dataset (0 Finland authorizations); Idebenone is generally known as a mitochondrial-support/antioxidant CoQ10 analogue |
| Predicted New Indication | Hepatic porphyria |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this candidate record. Based on general pharmacological knowledge, Idebenone is a short-chain benzoquinone that acts on the mitochondrial electron transport chain and functions as an antioxidant; it has no formally documented approved indication in the present dataset, and Idebenone is not currently marketed in Finland (0 authorizations).
The TxGNN-generated rationale for hepatic porphyria explicitly flags a weak mechanistic link: Idebenone's mitochondrial/antioxidant activity does not directly overlap with the heme biosynthesis pathway that is the core pathology of porphyria. The stated hypothesis is that oxidative stress could be a shared secondary contributor between the two conditions, but this is speculative rather than evidence-based.
Given the absence of any supporting clinical trials or literature, this prediction should be treated as a hypothesis-generation signal from the knowledge graph rather than a mechanistically grounded repurposing candidate at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Note: A blocking data gap exists — TFDA/Fimea package insert warnings and contraindications have not yet been retrieved (DG001), so no safety-related decision can currently be supported by this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is at decision stage S0 with evidence level L5 — supported only by a knowledge-graph score, with zero clinical trials, zero literature, and a mechanistic rationale the model itself describes as weak. Idebenone is also not marketed in Finland, and core safety data (warnings/contraindications) is missing (blocking gap).
To proceed, the following is needed:
- Idebenone package insert / TFDA-equivalent safety data (warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action and original approved indication data (DG002)
- Preclinical or mechanistic studies directly linking mitochondrial/antioxidant pathways to heme biosynthesis or porphyria pathophysiology
- Any emerging clinical trial or case-report evidence in hepatic porphyria before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.